Is Melatonin Safe for Stroke Patients?

Melatonin has not been flagged as dangerous for stroke patients in the small number of studies that have tested it, but the honest answer is that rigorous human safety data barely exist. Almost everything we know about melatonin and stroke comes from animal experiments, which have been remarkably encouraging. A handful of small clinical trials in stroke patients reported no serious adverse effects, yet those trials were designed to look for early signals of benefit, not to establish safety at the level your neurologist would want before making a recommendation. The gap between the promising lab science and the thin clinical evidence is where the real story sits.

Why Researchers Think Melatonin Could Help After a Stroke

The interest in melatonin for stroke is not random. It stems from the hormone’s unusual range of protective actions in the brain. Melatonin directly neutralizes harmful reactive molecules and also boosts the brain’s own antioxidant enzyme systems.¹ When a stroke cuts off blood flow and then blood returns, a surge of oxidative damage and inflammation worsens the initial injury. Melatonin appears to counteract several of those destructive cascades simultaneously.

One particularly important line of research involves the blood-brain barrier, the tightly sealed lining of blood vessels that keeps toxic substances out of brain tissue. After a stroke, this barrier breaks down, leading to swelling and further damage. In lab models, melatonin preserved barrier integrity by inhibiting an enzyme that chews through the structural proteins holding the barrier together.² A separate study in a rat stroke model confirmed that melatonin treatment significantly reduced barrier leakiness at 24, 48, and 72 hours after injury.³

Melatonin also nudges the brain’s immune cells, called microglia, away from a damaging inflammatory state and toward a repair-promoting state. Studies in mice have shown that melatonin treatment after an ischemic stroke pushed microglia toward this anti-inflammatory profile, reducing the production of inflammatory molecules and decreasing the infiltration of immune cells from the bloodstream into the injured brain.⁴⁵ On top of that, melatonin protected mitochondria inside brain cells, preserving their ability to produce energy and preventing the chain of events that leads to programmed cell death.⁶

A 2024 systematic review pulled all of these threads together, concluding that melatonin showed beneficial effects across nearly every aspect of the damage caused by stroke and reperfusion injury in animal models, from reducing the size of the damaged area and brain swelling to improving neurological function and protecting the blood-brain barrier.⁷

What the Human Evidence Actually Shows

Here is where the picture gets much thinner. The most directly relevant trial was a double-blind, placebo-controlled study of 65 patients with acute ischemic stroke who were not eligible for clot-dissolving therapy. Patients received either 20 mg of oral melatonin once daily for five days or a placebo, alongside standard stroke care.⁸ The trial was described as a pilot, meaning it was primarily designed to test whether the concept was worth pursuing in larger studies. That 20 mg dose is considerably higher than what most people take as a sleep aid, and the trial did not report safety alarms. But 65 patients is far too few to detect uncommon side effects.

A separate study looked at ramelteon, a prescription drug that activates melatonin receptors, given to elderly stroke patients to prevent delirium. No patient experienced oversedation, neurological worsening, or any other harmful effect linked to the treatment.⁹ That’s reassuring for the general tolerability question, though it does not tell us much about melatonin itself at higher doses or over longer periods.

The bottom line on human safety data is that no trial has found a red flag, but no trial has been large or long enough to rule one out with confidence. If you are a stroke survivor wondering whether to take melatonin, the absence of reported harm is mildly encouraging, but it is not the same as proven safety. This is a conversation your medical team should weigh in on, because your specific medications, stroke type, and health status all matter.

A Clue From Blood Clot Therapy

One of the most dangerous complications of stroke treatment is hemorrhagic transformation, where a clot-dissolving drug like tPA successfully restores blood flow but causes bleeding into the weakened brain tissue. In mouse experiments, tPA treatment alone significantly increased this hemorrhagic complication, but when melatonin was given alongside tPA, that bleeding risk was effectively reversed.¹⁰ Melatonin also reduced the increase in brain damage that tPA itself sometimes causes in these models.¹¹

If this held up in humans, it would be a significant finding, because hemorrhagic transformation is one of the scariest risks of clot-busting treatment. But these are mouse data, and the doses and timing do not translate directly to a hospital setting. No human trial has yet tested melatonin as an add-on to tPA therapy.

Hemorrhagic Stroke Is a Separate Question

Most of the research focus has been on ischemic stroke, the kind caused by a blood clot. Hemorrhagic stroke, caused by bleeding in the brain, is a different beast. A review of animal studies found that melatonin’s antioxidant and anti-inflammatory properties were also neuroprotective in experimental models of hemorrhagic stroke.¹²

One observational study in humans looked at patients with intracerebral hemorrhage who happened to receive melatonin during their hospital stay. After matching patients for severity and other factors, the melatonin group had lower mortality at discharge compared to the control group, but this difference did not reach statistical significance, and there was no meaningful difference in functional outcomes at 90 days.¹³ Because this was observational rather than a controlled experiment, the results suggest that melatonin was at least not causing obvious harm in hemorrhagic stroke patients, but they cannot show benefit either. If you have had a hemorrhagic stroke, the safety question is even less settled than for ischemic stroke, and caution is especially warranted.

Post-Stroke Sleep Disruption and Where Melatonin Fits

Stroke does not just damage brain tissue; it disrupts the body’s internal clock. Animal research has shown that stroke causes immediate shifts in the timing of melatonin secretion, followed by days of instability where the body’s melatonin rhythm lurches back and forth unpredictably.¹⁴ This circadian chaos likely contributes to the insomnia, excessive daytime sleepiness, and fragmented sleep that plague many stroke survivors.

A rat study found that daily melatonin supplementation during the subacute phase after stroke reduced sleep fragmentation, improved deep sleep, and partially restored the disrupted circadian pattern.¹⁵ A small human study in post-stroke patients with insomnia found that three weeks of melatonin use reduced daytime sleepiness scores and improved sleep quality compared to controls.¹⁶

Interestingly, one animal study found that melatonin alone had only modest effects on REM sleep recovery after stroke, but when combined with exercise, the improvements were more pronounced.¹⁷ That finding mirrors a broader theme in stroke recovery research: single interventions rarely do the job alone, and combinations tend to work better. For stroke survivors struggling with sleep, melatonin may have a role, but the evidence is strongest when it is part of a broader approach that includes physical rehabilitation.

Long-Term Recovery and Brain Repair

Beyond the acute phase, there is emerging evidence that melatonin may support longer-term brain repair. Studies in mice have reported that melatonin enhanced neurogenesis, the birth of new brain cells, and promoted neuroplasticity, the brain’s ability to rewire itself after injury.¹⁸ One study in middle-aged mice found that melatonin treatment after a permanent stroke decreased the area of dead tissue, increased the density of dendritic spines (the tiny protrusions on brain cells where connections form), and improved behavioral recovery.¹⁹ The age of those mice matters, because most stroke patients are older, and many neuroprotective agents that work in young animals fail in older ones.

In another mouse study, delayed melatonin administration, meaning treatment started well after the stroke rather than immediately, still promoted cell survival and was associated with long-lasting improvements in motor coordination and reductions in anxiety-like behavior.²⁰ If this translates to humans, it would mean the window for melatonin to help is not limited to the first hours after a stroke. But the usual caveat applies: the translation from mouse to human is uncertain.

Drug Interactions Stroke Patients Should Know About

Stroke patients typically take multiple medications, including blood thinners, blood pressure drugs, and statins. Melatonin is primarily broken down by a liver enzyme called CYP1A2. A study that screened several common drugs for interactions with melatonin’s metabolism found that most drugs tested at therapeutic doses, including common painkillers, did not meaningfully interfere with how the body processes melatonin. Only one potent inhibitor of that enzyme pathway caused a clinically relevant interaction.²¹

That said, the drug that most commonly inhibits CYP1A2 in everyday practice is fluvoxamine, an antidepressant sometimes prescribed after stroke for depression or anxiety. Ciprofloxacin, an antibiotic, is another strong inhibitor. If you take either of these, melatonin could build up to much higher levels in your blood than expected, potentially increasing drowsiness or other effects. Conversely, smoking cigarettes strongly activates CYP1A2, meaning smokers may metabolize melatonin faster and get less effect from a given dose.

Melatonin has also been reviewed for its effects on the coagulation system, the cascade that forms blood clots. Since stroke patients are frequently on anticoagulants or antiplatelet drugs, any substance that influences clotting deserves scrutiny.²² Some lab evidence suggests melatonin can influence platelet behavior, though the clinical significance of this at typical supplement doses is unclear. If you are on warfarin or another anticoagulant, mention melatonin use to your prescriber, because even a mild effect on clotting could matter when your blood chemistry is being carefully managed.

The Dose Problem

In animal studies, timing and dose both mattered considerably. A rat study found that melatonin was effective when given within two hours of stroke onset, a window that has obvious practical limitations in the real world.²³ The effective dose range also appears to vary by sex and hormonal status. In female rats with normal estrogen levels, moderate doses worked well, but high doses did not. In female rats whose ovaries had been removed, only much larger doses were effective. This kind of hormonal influence on drug response has been a headache in neuroprotection research generally, and it complicates any attempt to set a one-size-fits-all human dose.

The single completed human pilot trial used 20 mg per day, far above the 0.5 to 5 mg range most people use for sleep. Whether that dose is optimal, necessary, or more than needed for stroke patients remains unknown. Researchers in the systematic review noted that figuring out the right dose and timing for human stroke treatment is one of the major unresolved questions in this field.⁷

Supplement Quality Is a Real Concern

Even if melatonin turns out to be safe and beneficial for stroke patients, there is a practical problem that rarely gets enough attention: the supplements themselves are unreliable. A study that tested commercial melatonin products found that the actual melatonin content ranged from 83% less than the label claimed to 478% more. Variability between different lots of the same product was as high as 465%. On top of that, serotonin, a controlled substance and a neurologically active molecule, was detected in eight of the supplements tested.²⁴

For a healthy adult using melatonin to fall asleep faster, this variability is an annoyance. For a stroke patient on multiple medications with a vulnerable brain, it becomes a genuine safety issue. You might think you are taking 3 mg and actually be taking 15, or you might be ingesting serotonin without knowing it. If you are a stroke patient who decides to try melatonin, pharmaceutical-grade formulations, where available, offer more reliable dosing than over-the-counter supplements.

What Low Melatonin Levels After Stroke May Tell Us

A separate line of research has looked at melatonin not as a treatment but as a biomarker. A study of patients with acute ischemic stroke found that lower salivary melatonin levels were associated with worse short-term prognosis, and that melatonin levels had good predictive ability for outcomes.²⁵ This does not necessarily mean that giving melatonin would fix the prognosis. Low melatonin could simply be a marker of more severe circadian disruption, more extensive brain damage, or greater physiological stress. But it does suggest that melatonin levels and stroke outcomes are intertwined in ways we do not fully understand yet, and it adds another reason to watch this area of research as it develops.

Melatonin’s Neuropsychiatric Effects After Stroke

Anxiety and behavioral changes after stroke are common and often undertreated. In mouse experiments, delayed melatonin administration after a mild stroke reduced hyperactivity and anxiety-like behavior alongside its effects on motor recovery.²⁰ Given that post-stroke anxiety and depression affect a large share of survivors and can interfere with rehabilitation, even modest neuropsychiatric benefits would be worth having. Whether melatonin can deliver those benefits in humans who have had a stroke is unstudied in any rigorous way. But the observation that it reduced anxiety-like behavior in animals, alongside its known sleep benefits, makes it a candidate worth investigating for the constellation of sleep, mood, and behavioral symptoms that often travel together after stroke.